InCa
Publikationen
2022
Guo, C., R. Wan, Y. He, S.-H. Lin, J. Cao, Y. Qiu, T. Zhang, Q. Zhao, Y. Niu, Y. Jin, H.-Y. Huang, X. Wang, L. Tan, R. K. Thomas, H. Zhang, L. Chen, K.-K. Wong, L. Hu and H. Ji (2022). "Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer." Nature Cancer 3(5): 614-628. InCa doi.org/10.1038/s43018-022-00358-1.
Lategahn, J., H. L. Tumbrink, C. Schultz-Fademrecht, A. Heimsoeth, L. Werr, J. Niggenaber, M. Keul, F. Parmaksiz, M. Baumann, S. Menninger, E. Zent, I. Landel, J. Weisner, K. Jeyakumar, L. Heyden, N. Russ, F. Müller, C. Lorenz, J. Brägelmann, I. Spille, T. Grabe, M. P. Müller, J. M. Heuckmann, B. M. Klebl, P. Nussbaumer, M. L. Sos and D. Rauh (2022). "Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors." Journal of Medicinal Chemistry 65(9): 6643-6655. InCa doi.org/10.1021/acs.jmedchem.1c02080.
Montinaro, A., I. Areso Zubiaur, J. Saggau, A. L. Kretz, R. M. M. Ferreira, O. Hassan, E. Kitzig, I. Muller, M. A. El-Bahrawy, S. von Karstedt, D. Kulms, G. Liccardi, J. Lemke and H. Walczak (2022). "Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers." Cell Death Differ 29(3): 492-503. InCa doi.org/10.1038/s41418-021-00869-x.
Pindzola, G. M., R. Razzaghi, R. N. Tavory, H. T. Nguyen, V. M. Morris, M. Li, S. Agarwal, B. Huang, T. Okada, H. C. Reinhardt, G. Knittel, H. Kashkar, R. M. Young, S. Pittaluga and J. R. Muppidi (2022). "Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma." Blood. InCa doi.org/10.1182/blood.2022015926.
Ratz, L., C. Brambillasca, L. Bartke, M. A. Huetzen, J. Goergens, O. Leidecker, R. D. Jachimowicz, M. van de Ven, N. Proost, B. Siteur, R. de Korte-Grimmerink, P. Bouwman, E. M. Pulver, R. de Bruijn, J. Isensee, T. Hucho, G. Pandey, M. van Lohuizen, P. Mallmann, H. C. Reinhardt, J. Jonkers and J. Puppe (2022). "Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer." Breast Cancer Research 24(1): 41. InCa & SMOOSE doi.org/10.1186/s13058-022-01534-y.
Werr, L., D. Plenker, M. A. Dammert, C. Lorenz, J. Brägelmann, H. L. Tumbrink, S. Klein, A. Schmitt, R. Büttner, T. Persigehl, K. M. Shokat, F. T. Wunderlich, A. M. Schram, M. Peifer, M. L. Sos, H. C. Reinhardt and R. K. Thomas (2022). "CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization." Mol Cancer Ther 21(5): 821–830. InCa doi.org/10.1158/1535-7163.MCT-21-0820.
2021
Bebber, C. M., E. S. Thomas, J. Stroh, Z. Chen, A. Androulidaki, A. Schmitt, M. N. Höhne, L. Stüker, C. de Pádua Alves, A. Khonsari, M. A. Dammert, F. Parmaksiz, H. L. Tumbrink, F. Beleggia, M. L. Sos, J. Riemer, J. George, S. Brodesser, R. K. Thomas, H. C. Reinhardt and S. von Karstedt (2021). "Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes." Nat Commun 12(2048): 1–19. InCa doi.org/10.1038/s41467-021-22336-4.
Bebber, C. M. and S. von Karstedt (2021). "Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)." Molecular & Cellular Oncology 8(4): 1933871. InCa doi.org/10.1080/23723556.2021.1933871.
Biagi, C. A. O., S. S. Cury, C. P. Alves, N. Rabhi, W. A. Silva, S. R. Farmer, R. F. Carvalho and M. L. Batista (2021). "Multidimensional Single-Nuclei RNA-Seq Reconstruction of Adipose Tissue Reveals Adipocyte Plasticity Underlying Thermogenic Response." Cells 10(11): 3073. InCa doi.org/10.3390/cells10113073.
Bragelmann, J., C. Lorenz, S. Borchmann, K. Nishii, J. Wegner, L. Meder, J. Ostendorp, D. F. Ast, A. Heimsoeth, T. Nakasuka, A. Hirabae, S. Okawa, M. A. Dammert, D. Plenker, S. Klein, P. Lohneis, J. Gu, L. K. Godfrey, J. Forster, M. Trajkovic-Arsic, T. Zillinger, M. Haarmann, A. Quaas, S. Lennartz, M. Schmiel, J. D'Rozario, E. S. Thomas, H. Li, C. A. Schmitt, J. George, R. K. Thomas, S. von Karstedt, G. Hartmann, R. Buttner, R. T. Ullrich, J. T. Siveke, K. Ohashi, M. Schlee and M. L. Sos (2021). "MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I." Nat Commun 12(1): 5505. InCa doi.org/10.1038/s41467-021-25728-8.
Chen, M., R. Chen, Y. Jin, J. Li, X. Hu, J. Zhang, J. Fujimoto, S. M. Hubert, C. M. Gay, B. Zhu, Y. Tian, N. McGranahan, W.-C. Lee, J. George, X. Hu, Y. Chen, M. Wu, C. Behrens, C.-W. Chow, H. H. N. Pham, J. Fukuoka, J. Wu, E. R. Parra, L. D. Little, C. Gumbs, X. Song, C.-J. Wu, L. Diao, Q. Wang, R. Cardnell, J. Zhang, J. Wang, X. Le, D. L. Gibbons, J. V. Heymach, J. Jack Lee, W. N. William, C. Cheng, B. Glisson, I. Wistuba, P. Andrew Futreal, R. K. Thomas, A. Reuben, L. A. Byers and J. Zhang (2021). "Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer." Nat Commun 12(6655): 1–13. InCa doi.org/10.1038/s41467-021-26821-8.
Quambusch, L., L. Depta, I. Landel, M. Lubeck, T. Kirschner, J. Nabert, N. Uhlenbrock, J. Weisner, M. Kostka, L. M. Levy, C. Schultz-Fademrecht, F. Glanemann, K. Althoff, M. P. Muller, J. T. Siveke and D. Rauh (2021). "Cellular model system to dissect the isoform-selectivity of Akt inhibitors." Nat Commun 12(1): 5297. InCa www.ncbi.nlm.nih.gov/pubmed/34489430.
Rosswog, C., C. Bartenhagen, A. Welte, Y. Kahlert, N. Hemstedt, W. Lorenz, M. Cartolano, S. Ackermann, S. Perner, W. Vogel, J. Altmüller, P. Nürnberg, F. Hertwig, G. Göhring, E. Lilienweiss, A. M. Stütz, J. O. Korbel, R. K. Thomas, M. Peifer and M. Fischer (2021). "Chromothripsis followed by circular recombination drives oncogene amplification in human cancer." Nat Genet 53: 1673–1685. SMOOSE, SysMED-NB & InCa doi.org/10.1038/s41588-021-00951-7.
Schaufler, D., D. F. Ast, H. L. Tumbrink, N. Abedpour, L. Maas, A. E. Schwabe, I. Spille, S. Lennartz, J. Fassunke, M. Aldea, B. Besse, D. Planchard, L. Nogova, S. Michels, C. Kobe, T. Persigehl, T. Westphal, S. Koleczko, R. Fischer, J. P. Weber, J. Altmuller, R. K. Thomas, S. Merkelbach-Bruse, O. Gautschi, L. Mezquita, R. Buttner, J. Wolf, M. Peifer, J. Bragelmann, M. Scheffler and M. L. Sos (2021). "Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer." Npj Precision Oncology 5(1). InCa doi.org/10.1038/s41698-021-00241-9.
2020
Cartolano, M., N. Abedpour, V. Achter, T.-P. Yang, S. Ackermann, M. Fischer, and M. Peifer (2020). "CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature." Sci Rep 10(19316): 1–10. doi.org/10.1038/s41598-020-75753-8.
Clemente, L. P., M. Rabenau, S. Tang, J. Stanka, E. Cors, J. Stroh, C. Culmsee, and S. von Karstedt (2020). "Dynasore Blocks Ferroptosis through Combined Modulation of Iron Uptake and Inhibition of Mitochondrial Respiration." Cells 9(10): 2259. doi.org/10.3390/cells9102259.
Jiao, H., L. Wachsmuth, S. Kumari, R. Schwarzer, J. Lin, R. O. Eren, A. Fisher, R. Lane, G. R. Young, G. Kassiotis, W. J. Kaiser, and M. Pasparakis (2020). "Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation." Nature: 1–5. doi.org/10.1038/s41586-020-2129-8.
Klein, S., A. Quaas, K.-W. Noh, M. Cartolano, N. Abedpour, C. Mauch, J. Quantius, H. C. Reinhardt, R. Buettner, M. Peifer, and D. Helbig (2020). "Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy." Clin Cancer Res 26(21): 5638–5645. doi.org/10.1158/1078-0432.CCR-20-1899.
Lategahn, J., J. Hardick, T. Grabe, J. Niggenaber, K. Jeyakumar, M. Keul, H. L. Tumbrink, C. Becker, L. Hodson, T. Kirschner, P. Klövekorn, J. Ketzer, M. Baumann, S. Terheyden, A. Unger, J. Weisner, M. P. Müller, W. A. L. van Otterlo, S. Bauer, and D. Rauh (2020). "Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach." J Med Chem 63(20): 11725–11755. doi.org/10.1021/acs.jmedchem.0c00870.
Schwarzer, R., L. Laurien, and M. Pasparakis (2020). "New insights into the regulation of apoptosis, necroptosis, and pyroptosis by receptor interacting protein kinase 1 and caspase-8." Curr Opin Cell Biol 63: 186--193. www.sciencedirect.com/science/article/pii/S0955067420300272.
Tumbrink, H. L., A. Heimsoeth, and M. L. Sos (2020). "The next tier of EGFR resistance mutations in lung cancer." Oncogene: 1–11. doi.org/10.1038/s41388-020-01510-w.
von Karstedt, S., and H. Walczak (2020). "An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer." Cell Death Discovery 6(14): 1–8. doi.org/10.1038/s41420-020-0249-4.
2019
Quambusch, L., I. Landel, L. Depta, J. Weisner, N. Uhlenbrock, M. P. Muller, F. Glanemann, K. Althoff, J. T. Siveke, and D. Rauh (2019). "Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity." Angewandte Chemie-International Edition 58(52): 18823-18829. www.ncbi.nlm.nih.gov/pubmed/31584233.